BAJAJ BROKING

Notification close image
No new Notification messages
card image
Euro Pratik Sales Ltd IPO
Apply for the Euro Pratik Sales Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Aptus Pharma IPO: Things Smart Investors Need to Know

Aptus Pharma Ltd, incorporated in 2010, is a pharmaceutical company engaged in the marketing and distribution of finished formulations across multiple therapeutic areas. Its product portfolio covers antacids, antibiotics, anti-inflammatories, cardiology and antidiabetic medicines, neuropsychiatry drugs, nutraceuticals, dental care, and injectable parenterals. The business operates through four divisions—Aptus Pharma for acute therapies, Aptus CD Care for chronic therapies, Aptus Wellcare for wellness products, and Aptus Global for overseas markets. As of March 31, 2025, the company offered 194 formulations in more than eleven therapeutic segments, supported by warehousing facilities in Ahmedabad and a network of 125 distributors, managed by a sales team of 54 field staff.

Unlike traditional manufacturing companies, Aptus Pharma follows a contract manufacturing model. It does not own plants but collaborates with seven partner units through a mix of formal loan and license agreements and informal arrangements based on purchase orders. This asset-light approach allows the company to distribute a wide variety of dosage forms such as tablets, capsules, syrups, softgels, and suspensions. With 70 employees and a growing presence in both domestic and international markets, Aptus Pharma’s IPO offers investors insight into a distribution-driven pharmaceutical business with diversified product coverage.

For more details, visit the Aptus Pharma IPO page.

Aptus Pharma IPO Details and Objectives

Details

Information

IPO Date

September 23, 2025 to September 25, 2025

Issue Size

18,60,000 shares

(aggregating up to ₹13.02 Cr)

Price Band

₹65 to ₹70 per share

Lot Size

2000 shares

Listing At

SME BSE

Market Maker

Market-Hub Stock Broking Pvt.Ltd.

Purpose of the IPO

  • Capital Expenditure for Office Premises with furniture and Industrial Racks

  • Funding the working capital requirements of the company

  • General Corporate Purpose

Timeline of Aptus Pharma IPO

Event

Date

IPO Open Date

Tue, Sep 23, 2025

IPO Close Date

Thu, Sep 25, 2025

Tentative Allotment

Fri, Sep 26, 2025

Initiation of Refunds

Mon, Sep 29, 2025

Credit of Shares to Demat

Mon, Sep 29, 2025

Tentative Listing Date

Tue, Sep 30, 2025

Cut-off time for UPI mandate confirmation

5 PM on Thu, Sep 25, 2025

Pricing & Lot Size of Aptus Pharma IPO

Price Band for the IPO

  •  ₹65 to ₹70 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

2

4,000

₹2,80,000

Individual investors (Retail) (Max)

2

4,000

₹2,80,000

S-HNI (Min)

3

6,000

₹4,20,000

S-HNI (Max)

7

14,000

₹9,80,000

B-HNI (Min)

8

16,000

₹11,20,000

How to Apply for the Aptus Pharma IPO?

Online Application Process

  • Log in to Your Trading Account: Access your trading account through your broker’s platform.

  • Navigate to the IPO Section: Go to the IPO section to view active IPO listings.

  • Select Aptus Pharma IPO: Find "Aptus Pharma IPO" and click on the ‘Apply’ button.

  • Enter Application Details: Specify the number of lots (minimum lot size: 2000 shares) and the bid price within the range of ₹65 to ₹70 per share.

  • Provide Your UPI ID: Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.

  • Review and Submit: Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on September 25, 2025, to complete your application process.

Additional Read- How to Apply for the Aptus Pharma IPO?

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹6.22 crore in FY23 to ₹21.92 crore as of March 2025.

  • Total income: Reached ₹24.64 crore in FY25.

  • Profit After Tax (PAT): Stood at ₹3.10 crore for March 2025.

  • Net Worth: Recorded at ₹6.97 crore in FY25.

  • Total Borrowing: Recorded at ₹10.36 crore (March 2025), growing steadily over the years.

  • EBITDA: Stood at ₹4.76 crore in March 2025.

Recent Performance and Growth Prospects

  • The company has shown consistent improvement in its overall asset base over the past few years.

  • Its income levels have reflected steady expansion, signalling strengthening operations.

  • Profitability has improved, highlighting efficient cost management and market presence.

  • The net worth position has strengthened, indicating a more stable financial base.

  • Borrowings have increased gradually, supporting business growth and expansion activities.

  • Operating performance has remained healthy, reflecting a sustainable earnings profile.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company relies on third-party manufacturers, which may expose it to risks related to quality, supply timelines, and dependency on external partners.

  • Expansion and growth depend on maintaining strong distribution networks and consistent demand across therapeutic areas, which could face challenges from market competition or regulatory changes.

Opportunities and Growth Potential

  • The business operates with an asset-light model, enabling it to diversify its product offerings across acute, chronic, and wellness segments without heavy investment in infrastructure.

  • Growing presence in both domestic and international markets positions the company to capture demand across multiple therapeutic areas and enhance long-term scalability.

Key Performance Indicator (KPI)

KPI

Values

ROE

44.50%

ROCE

45.66%

Debt/Equity

1.49

RoNW

44.50%

EBITDA Margin

19.31%

Aptus Pharma IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Bigshare Services Pvt.Ltd. 

Interactive Financial Services Ltd.

Company Address of Aptus Pharma Ltd

Aptus Pharma Ltd. Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Ahmedabad, Gujarat, 382427

Phone: +91 76004 27827

Email: info@aptuspharma.com

Website: https://aptus-pharma.com/

Conclusion

Aptus Pharma IPO provides an overview of a pharmaceutical company that works through a marketing and distribution-driven model. With divisions focused on acute therapies, chronic care, wellness, and exports, the business maintains a diverse product portfolio across multiple therapeutic areas. Its reliance on contract manufacturing allows for flexibility in production while keeping the business asset-light.

The IPO objectives include funding working capital needs, office-related expenditure, and general corporate purposes. Investors are presented with details on issue size, timelines, pricing, and application process, offering insight into the company’s structure and financial standing without ownership of manufacturing facilities.

Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Aptus Pharma IPO.

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹6400+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|